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Abstract
Antimicrobial resistance (AMR) has the potential to threaten tens of millions of lives and poses major global
economic and development challenges. As the AMR threat grows, it is increasingly important to strengthen the
scientific evidence base on AMR policy interventions, to learn from existing policies and programmes, and to
integrate scientific evidence into the global AMR response.
While rigorous evaluations of AMR policy interventions are the ideal, they are far from the current reality. To
strengthen this evidence base, we describe a framework for planning, conducting and disseminating research on
AMR policy interventions. The framework identifies challenges in AMR research, areas for enhanced coordination
and cooperation with decision-makers, and best practices in the design of impact evaluations for AMR policies.
This framework offers a path forward, enabling increased local and global cooperation, and overcoming common
limitations in existing research on AMR policy interventions.
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Introduction
Antimicrobial resistance (AMR) — the process by which
microbes acquire resistance to antimicrobial medicines
— is widely recognised as a serious threat to global pub-
lic health. The likelihood of drug resistance increases
when microbes are exposed to antimicrobials and, unlike
previous generations, we can no longer count on the de-
velopment of new drugs to overcome this threat [1–3].
The development of resistance has been accelerated by
overuse of antimicrobials for medical and agricultural
purposes. AMR now threatens tens of millions of lives
[4], in addition to posing major global economic and de-
velopment challenges [5].
AMR is politically, economically and microbially diffi-
cult to tackle from a policy perspective. Efforts to evalu-
ate AMR interventions would be significantly improved
by increasing investments in monitoring and surveillance
for antimicrobial resistance. Controlling AMR will re-
quire a suite of effective antimicrobial stewardship and
conservation strategies to ensure the appropriate use of
antimicrobials [6], in addition to substantial inter-
national cooperation on the regulation and surveillance
of antimicrobials and their use [7–11]. Substantial re-
search is needed to generate evidence on the effects and
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effectiveness of various possible AMR policies and to en-
sure that health system investments in AMR are evi-
dence informed. Existing research has created little
clarity about what interventions are best suited to
achieve AMR goals across contexts, cultures and health
systems. Many efforts to reduce AMR are designed as
policies to reduce the use of antimicrobials; in this
manuscript, when we refer to ‘AMR policy’, we refer also
to these antimicrobial use policies. Policy recommenda-
tions for AMR have changed little since the late 1990s
[4, 12–16]. Worldwide, millions of dollars are invested
annually in public programmes to raise awareness about
AMR, educate health professionals on appropriate pre-
scribing, and decrease antimicrobial consumption in the
health and agricultural sectors. Despite major financial
and political investments, it has been difficult to link
these programmes to concrete improvements in anti-
microbial use, resistance or health outcomes more gen-
erally [6, 17], particularly as major surveillance and
information gaps impede the global response to AMR
[18] (Box 1).
As the threat posed by AMR grows, it is increasingly
important to strengthen the scientific evidence base on
AMR policy interventions, to learn from existing policies
and programmes, and integrate scientific evidence into
the global AMR response [6]. The goal of this paper is
to develop a framework that facilitates the strengthening
of this evidence base. This paper is not intended as a
formal research prioritisation process but, rather, builds
upon the findings from recent systematic reviews of in-
terventions to reduce antimicrobial consumption [6, 17,
21, 25] and efforts by others to strengthen research on
AMR and public health [17, 23, 26–30], and aims to
draw insights for improving the planning, conduct and
dissemination of research to evaluate AMR policy inter-
ventions (Fig. 1). The framework identifies challenges in
AMR evaluation research, areas for enhanced coordin-
ation and cooperation with policy-makers, and best-
Fig. 1 Framework for prioritising, conducting and disseminating AMR policy interventions
Box 1
Current state of the evidence base on AMR policy interventions
Around the world, 129 governments are currently in the process of
developing or implementing a National Action Plan to address
antimicrobial resistance [19]
Global capacity for AMR surveillance is lacking; discrepancies between
methods and monitoring systems, data quality concerns and lack of
representativeness make it challenging to compare AMR data between
countries [20]
Many evaluations of AMR policy interventions are conducted
retrospectively by academics who were not involved in the design or
implementation of the intervention [6, 21]
A systematic review of experimental and quasi-experimental studies
evaluating government policy interventions to reduce the use of
antimicrobials [6, 22] found that 30 of the 69 studies used low-quality
study designs, such as uncontrolled before–after designs, which severely
limits the validity of their findings. Among these 69 studies, only 4 used
a randomised controlled design which is considered the gold standard
for evaluating interventions.
Another systematic review of 221 interventions for improving antibiotic
prescribing among hospital inpatients found the quality of the reporting
for the 163 non-randomised studies was so poor that it was difficult for
professionals to use the research findings or to implement interventions
that were shown to be useful; further, this systematic review found that
no useful evidence could be gleaned from studies using controlled
before–after and non-randomised trial designs [17]
Reporting of AMR policy intervention studies is weak; studies often fail
to describe the intervention in sufficient detail for replication and many
do not report the reason the intervention is expected to work [21]
In the broader field of public health, researchers have estimated that at
least 50% of published research is not sufficiently clear, complete or
accurate for others to interpret or use [23, 24]
There are no standardised measures and metrics for AMR research;
many AMR intervention studies report antimicrobial use in defined daily
dose per 1000 population or a simple prescribing rate [21]
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practices for overcoming common limitations in evaluat-
ing AMR policies. Some of these challenges are specific




AMR researchers need to prioritise the study of ‘what’
works, ‘when’ it works, ‘why’ it works, and ‘what’ ele-
ments are necessary for its success.
AMR needs better mechanisms for prioritising import-
ant research questions that can shape effective action.
There has already been substantial research on the root
social and microbial causes of AMR [31–33] and we
argue that attention now needs to be focused on deter-
mining which interventions are effective at addressing
the underlying root causes of AMR, why these interven-
tions work, what elements are necessary to their success,
and in what contexts and circumstances these interven-
tions work. More evidence on all four questions would
be invaluable for policy planning [6, 17]. As the majority
of existing research evidence focuses on interventions in
high-income settings [6, 17], additional research on
these questions would particularly benefit low- and
middle-income countries (LMICs) and other resource
limited settings to identify policy interventions that can
be adapted to meet local needs and priorities.
More formally, research prioritisation can be improved
by undertaking structured prioritisation and consensus
processes in collaboration with stakeholder groups, in-
cluding policy-makers at different levels of government,
civil society, health professionals and research funders.
Research funders can support this work through oppor-
tunities for strategically funded research to address
AMR rather than relying on researcher-led operating
grants. For example, the Joint Programming Initiative on
Antimicrobial Resistance (JPIAMR) recently funded an
international workshop and formal consensus process to
develop 10 research priorities for behavioural ap-
proaches to develop more impactful hospital antimicro-
bial stewardship programmes [29]. The James Lind
Alliance in the United Kingdom, which provides a plat-
form for priority-setting partnerships between clinicians,
patients and carers, has produced a guidebook that out-
lines their method for identifying research uncertainties
and producing an agreed list of research priorities [34].
Research prioritisation processes can also highlight the
differences between research priorities in different con-
texts. Economic, political and cultural differences be-
tween countries and regions are likely to introduce new
priorities. A recent prioritisation exercise looking at glo-
bal health trial methodology found different research
priorities in LMICs compared with the United Kingdom
[35]. The Cochrane Collaboration has previously
published a special series on priority-setting that offers
guidance on topics such as applying an equity lens to
priority-setting [36] and effective stakeholder participa-
tion in priority-setting [37]. Formal prioritisation pro-
cesses would help drive research agendas at the
international level, such as those of JPIAMR, WHO, the
Food and Agriculture Organization of the United Na-
tions, and the World Organisation for Animal Health.
Recently, the WHO has engaged in formal priority-
setting exercises for AMR research and development,
first through a multi-criteria decision analysis exercise to
develop its list of priority pathogens for research and de-
velopment of new antimicrobials [38], and more recently
through the Global Antibiotic Research & Development
Partnership (GARDP). At the country level, such priori-
tisation processes can help drive national research fund-
ing, prompt updates to AMR national action plans, and
support maximal learning from national AMR actions.
Systematic reviews
Researchers need to use rigorous systematic reviews to
inform research prioritisation and to summarise the ef-
fectiveness of policy interventions.
Rigorous systematic reviews and evidence gap maps
can support the planning of policy interventions by en-
suring that they are adequately supported by evidence.
However, to be useful, these reviews must be high qual-
ity and regularly updated. Health Systems Evidence has
appraised and catalogued more than 50 systematic re-
views related to health systems and antimicrobial use
dating back to the year 2000, and this database shows
that the rigour and quality of these reviews is mixed
[39].
Conducting systematic reviews to summarise what we
currently know is an essential input for research priori-
tisation. Reviews can collate empirical evidence to an-
swer a specific research question [40] but they can also
map the availability of evidence to identify evidence
gaps. The Campbell Collaboration and others have re-
cently developed methodological guidance for creating
evidence gap maps [41]. Systematic reviews need to be
regularly updated to include new evidence as it arises, to
determine whether research gaps have been addressed,
and to determine whether the research question has
been satisfactorily answered or whether future, more re-
fined research is needed. Given that the current evidence
base on AMR policy is weak [6], policy decisions in the
near future will be informed by relatively weak signals
from the research base, which reinforces the need for
further evaluation.
Systematic reviews can also ensure that research ef-
forts are not wasted on questions that have already been
definitively answered [23, 42]. Although replication is
key to science, there is a point at which additional
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replication holds little additional value [26]. For example,
it has been definitively shown that hospital antimicrobial
stewardship interventions are effective at reducing anti-
microbial use compared to control and should be a
standard part of the AMR response [17]. Future research
can, instead, focus on optimising stewardship for differ-
ent contexts in order to maximise effects. This includes
opportunities to embrace a philosophy of radical incre-
mentalism, where a series of small evaluated changes
one after the other result in radical cumulative change
[43]. Finally, employing advanced analytical techniques,
such as network meta-analysis, in systematic reviews can
improve research prioritisation by enabling better ex-
ploration of heterogeneity in reviews of complex inter-
ventions [44].
More planned evaluations
Researchers need to work with stakeholders to ensure
that rigorous evaluations of all new AMR programmes
are the norm.
Researchers can actively advance progress on AMR by
ensuring that evaluations of policies become the norm.
While rigorous evaluations of all AMR interventions
would be ideal, at present, we are very far from this real-
ity [21]. Policy responses to AMR — from legislation
and government regulation to public awareness cam-
paigns — have played a major role in responding to
AMR, yet these policies are rarely conceptualised as
population health interventions and, as a result, are
rarely pilot-tested, reviewed or evaluated with sufficient
rigour to expand the AMR evidence base.
Without a culture of evaluation, we risk implementing,
maintaining and even spreading ineffective or inefficient
AMR policies, at great financial and opportunity costs.
Additionally, though policy-makers do not always see
their added value, there are political advantages in con-
ducting good impact evaluations; evaluation puts policy-
makers in the politically attractive position of continu-
ous policy improvement, enables them to ensure that re-
search assessing their initiative is appropriate, and
reduces political risk because they can acknowledge that
they are operating with imperfect information [45].
Where possible, researchers should advise and partner
with policy-makers to raise the rigour of evaluations,
simultaneously making progress on scientific questions.
In particular, researchers should advocate for the
development of protocols and evaluation plans a priori,
which will help minimise waste of public resources in in-
effective programmes by ensuring that the data collected
is appropriate to answer key policy-maker questions,
while also supporting implementation and future im-
provements in practice by ensuring that data is inter-
nationally comparable, and can feed into future evidence
syntheses of similar policy interventions.
Research that is responsive to stakeholder needs
AMR research needs to be planned to address policy-
makers’ questions about effectiveness, implementation,
costs and equity.
Moving from evidence to policy inevitably involves
consideration of pragmatic and ideological factors be-
yond evidence of effectiveness [46]. Researchers can sup-
port evidence-informed policy-making by considering, in
advance, the likely information needs of policy-makers.
In addition to effectiveness, decisions to pursue or pass
over various AMR policy interventions are likely to be
informed by their perceived cost-effectiveness, equity
and differential impacts based on gender, race and socio-
economic status, implementation challenges, and accept-
ability to diverse social groups. This is particularly true
in the case of LMICs, where resources are scarce and
where the level of evidence required before investing in
policy action may be substantially higher [45].
One simple and intuitive tool for enabling policy-
maker engagement in research planning is to use the
APEASE criteria [46] (Box 2). Originally created as a
framework for evaluating ideas for interventions,
APEASE offers a useful structure for framing research
questions and evidence needs in partnership with stake-
holders and for communicating policy-relevant research
findings. APEASE addresses many common stakeholder
concerns, including equality and equity considerations,
acceptability across a wide range of groups, and the
feasibility and practicality of an intervention in a given
context, while recognising important trade-offs. Con-
sider, for example, that both the clinical effectiveness
and cost-effectiveness of an intervention is irrelevant if
the intervention is unaffordable or infeasible given fund-
ing and resource constraints in a specific context. In
addition to the feasibility of implementation, it is useful
to consider whether the intervention should be, or can
be, equally applied across the whole population, and
whether it will reach its target population and intended
beneficiaries. Again, the inclusion of these additional re-
search questions in the planning phase will particularly
benefit policy-makers in lower-resource settings, who
must consider whether interventions from high-income
settings could translate effectively to their setting, given
the staff and resource limitations particular to their
context.
Box 2




Acceptability – public, professional, political
Side-effects/safety
Equality
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Research conduct
Better design of AMR interventions
Researchers need to use theory, frameworks and logic
models to design more coherent AMR policy
interventions.
Unfortunately, to date, the approach to designing
AMR policy interventions has been ad hoc and seems to
be guided by the ‘it seemed like a good idea at the time’
principle, rather than by an explicit process that con-
siders the determinants of the problem, relevant theory
and available empirical evidence [17, 21]. This strategy
has often resulted in poorly considered AMR policies
that, although designed to change attitudes, beliefs and
practices around antimicrobial use, cannot clearly articu-
late how their intervention will successfully bring about
this change [21]. Poorly designed policies may also fail
to recognise and address key AMR determinants, leading
to ineffective or sub-optimally effective interventions.
Researchers can improve the design of AMR policy in-
terventions by employing and advocating for the inclu-
sion of theory, frameworks and logic models in the early
stages of intervention design to describe how and why
an intervention is expected to work. These steps can
substantially address the common tendency in AMR to
re-invent the ‘square’ wheel rather than build on existing
evidence from behavioural and implementation science.
When planned without the use of theory, interventions
are more likely to be unclear about the behaviours and
outcomes targeted, and the means by which the inter-
vention will achieve its intended effect [17]. The process
of building such models can encourage researchers to
consider all aspects of the intervention and the existing
AMR evidence base. The United Kingdom Medical Re-
search Council has published a useful framework for de-
veloping and evaluating complex interventions [47, 48].
Other useful frameworks include the Behaviour Change
Wheel [46, 49] to guide intervention development, the
Theoretical Domains Framework to assess factors that
impact behaviour [50], and the Behaviour Change Tech-
niques taxonomy, which considers individual component
strategies employed to change behaviour (e.g. feedback
on behaviour, goal setting, prompts and cues) under the
umbrella of a larger intervention [51]. Finally, the use of
theories, frameworks and logic models also facilitate re-
search communication and dissemination, making clear
the considerations and circumstances that drove the ini-
tial hypothesis [50].
Better design of evaluations
Researchers need to ensure that AMR policy interven-
tions are evaluated using the most rigorous designs feas-
ible in the given circumstances.
When promoting a culture of AMR policy evaluation,
improving and strengthening the design of evaluations
should also be considered. One challenge in AMR re-
search has been a lack of differentiation between
programme evaluation (i.e. evaluating whether the local
programme achieved its goals) and research evaluation
(i.e. addressing generalisable concerns about what, when,
how and why an intervention works). While programme
evaluation is important, policy-making needs to be guided
by robust evidence generated using rigorous study designs.
AMR policy intervention research has been plagued by
poor quality and inappropriate evaluation methods. In a
recent systematic review, 30 of 69 included studies used
uncontrolled before–after designs and simple descriptive
methods that cannot control for important design con-
cerns, including bias, confounding and secular trends, and
are generally uninterpretable [6, 52, 53].
Overall, interventions should be evaluated using the most
rigorous study designs feasible in the given circumstances
in order to minimise bias and maximise the generalisability
of findings. The choice of evaluation design will be guided
by numerous factors, such as whether it is feasible to ran-
domise intervention sites, whether it is necessary to intro-
duce the intervention at all sites simultaneously, the
acceptability of having a no-intervention control group, and
the number of available intervention sites (Fig. 2).
The focus on education, attitudes and behaviour change
in AMR research, and the associated high likelihood of
contamination, will likely preclude the use of randomised
controlled trials (RCTs) with individuals (e.g. citizens, pa-
tients) as the units of randomisation in much of AMR pol-
icy intervention research. In most cases, a cluster RCT
should be considered the gold standard for AMR policy
intervention evaluations [54]. Cluster randomisation can
be done at numerous levels, although trade-offs exist be-
tween the number of available units (e.g. regional level)
and the risk of contaminations (e.g. provider level). There
are many possible cluster randomised trial designs, includ-
ing two arm trials, multi-arm trials and factorial designs
where two or more interventions can be implemented
simultaneously. Another cluster design, the stepped wedge
trial — where all sites start in the control arm and end in
the intervention arm, crossing over to intervention se-
quentially and in random order [55] — may have many
practical benefits for large policy evaluations where roll-
out of an intervention to all sites within a health system or
community is a requirement [56]. Figure 3 illustrates these
recommended evaluation designs.
Where random allocation is not feasible (either due to
an inadequate number of randomisation units being
available or because simultaneous implementation across
the health system is required) interrupted time series
(ITS) methods are the strongest study design for AMR
research [57]. However, adding a control group [58] or
additional sites with staggered implementation of inter-
ventions (multiple baselines ITS design [59]) can
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Fig. 2 Considerations when choosing a prospective evaluation design for AMR policy interventions
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strengthen this design. Researchers should pay particular
attention to whether an ITS design is appropriate for
their study. ITS designs are best used for evaluating
AMR interventions that have been implemented at a
clearly defined point in time [57]; many AMR studies
have inappropriately used this design to measure com-
plex interventions rolled out in stages across several
months or years. de Kraker et al. have carefully consid-
ered the validity and bias concerns associated with these
study designs and have published two excellent guides
for evaluating antimicrobial stewardship interventions,
which are also highly relevant to other AMR policy in-
terventions [52, 54].
Uncontrolled before–after study designs, which histor-
ically have been common in AMR research, should be
avoided if at all possible. The apparent effects of an
intervention using these designs are completely con-
founded by secular trends and concurrent events. Even
controlled before–after studies, which mitigate this
threat of confounding to a limited extent, should be
avoided unless there are at least two intervention sites
and two control sites; however, given more sites, other
more rigorous study designs may be feasible and prefera-
ble. Controlled before–after studies and non-randomised
trials are an option when randomisation is not possible
and there is an insufficient number of time intervals to
conduct an ITS; however, these designs should only be
considered as hypothesis generating. Figure 2 outlines
some of the methodological considerations for choosing
a prospective evaluation design.
Fig. 3 Recommended study designs for evaluating AMR policy interventions
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Iterative improvement on existing trials
AMR policy research needs to include head-to-head
comparisons of different intervention variations and pro-
mote radical incrementalism to enhance the effective-
ness of extant policies.
Researchers can advocate for the use of more rigorous
study designs and partner with policy-makers to ensure that
evaluations are appropriately conducted. To move beyond
effectiveness, research evaluations need to incorporate op-
portunities for addressing the other important AMR policy
questions described earlier, namely why interventions work
and what elements are necessary for their success. Once
the initial effectiveness of an AMR policy intervention has
been shown, there is an opportunity to conduct controlled
head-to-head comparisons of different intervention itera-
tions in the interest of optimisation, either through sequen-
tial trials comparing variations of the intervention, or using
factorial designs to evaluate whether the addition of co-
interventions meaningfully changes the intervention’s ef-
fectiveness. Evaluations can be facilitated by the develop-
ment of implementation laboratories, which involve close
collaboration between research teams and health systems
delivering implementation strategies at scale [60]. Trials
can also be designed to enhance the generalisability of
evaluation by including fidelity sub-studies to determine
whether an intervention was delivered and received as de-
signed, mechanistic sub-studies to determine whether the
intervention acted through the hypothesised pathways,
qualitative process evaluations to investigate experience
and acceptability, and economic evaluations [61].
A set of standard measures and metrics
Researchers need to define a set of core outcome mea-
sures for AMR research that address appropriate anti-
microbial prescribing, development of antimicrobial
resistance, and cost-effectiveness of policy interventions.
AMR lacks both an agreed-upon metric for evaluating
progress and a common system for measuring the scope
of the problem. Systematic reviews of interventions to re-
duce antimicrobial use have shown that researchers use a
wide range of prescribing and dispensing-focused metrics
[6, 17]. The Tripartite Monitoring and Evaluation Frame-
work [62] recently released by WHO, the Food and Agri-
culture Organization and the World Organisation for
Animal Health, is a useful starting point that suggests
many important One Health indicators for AMR; how-
ever, this framework lacks detail on operationalising these
measures. Researchers can have a significant impact in
these ongoing conversations by developing measures that
facilitate data sharing; for example, through an agreed
minimum dataset for collecting intervention data and a
core outcome set of measures to facilitate evaluations.
Consideration should also be given as to whether a core
outcome set can feed into AMR and antimicrobial use
surveillance to facilitate the use of routinely collected data
in impact evaluations.
A harmonised set of measures for conducting and
evaluating interventions serves three purposes. First, it
creates consistency between evaluations that facilitates
systematic reviews to inform evidence-informed policy-
making. Lack of a shared outcome measure is a common
challenge in public health systematic reviews and one
which limits the amount of evidence that can be rigor-
ously synthesised [63]. Second, creating a harmonised
set of measures offers the opportunity to include, as a
requirement, metrics beyond impact that are relevant to
stakeholders such as equity considerations and cost-
effectiveness. Finally, developing a set of harmonised
measures offers an opportunity to consider common
barriers to AMR policy implementation and to develop
standard measures and indicators that also address these
needs.
While there are substantial political and economic bar-
riers to improving data collection and evaluation, from a
metrics viewpoint, there are numerous successful initia-
tives that have adopted research governance principles
to improve data collection and comparability of research
studies, including the Core Outcome Measures in Effect-
iveness Trials (COMET) group [64] and ESSENCE for
Health Research [65]. Outcome Measures in Rheumatol-
ogy (OMERACT), for example, uses a data-driven, itera-
tive process to choose shared outcome measures across
four domains, and each selected measure must meet
three criteria – truth, discrimination and feasibility [66].
Research dissemination
Better reporting of interventions
Researchers need to register research protocols and
evaluation trials and use reporting guidelines and check-
lists to improve reporting quality.
An effective and coherent global response to AMR re-
quires full and transparent reporting of all aspects of AMR
intervention studies. Unfortunately, public health research
as a whole, and AMR research specifically, faces challenges
in this domain. Inaccessible research, partial reporting, and
publication bias are all common in AMR research [21, 67]
and limit opportunities for researchers and policy-makers
to learn from experiences in other contexts.
Researchers should register protocols, primary evalua-
tions of policy interventions (both RCTs and quasi-
experiments) and systematic reviews in trial registers.
Pre-registration of an evaluation helps address the ten-
dency to avoid publishing the results of research with
neutral or negative findings, which is common to much
of scientific research, and may be particularly common
in policy research where government partners may feel
that they lose credibility if a policy intervention is found
to be less effective than expected. The fields of clinical
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Table 1 Framework and recommendations for planning, conducting and disseminating evaluations of AMR policy interventions





Prioritise research to study
what works, when it works,
why it works, and what
elements are necessary to its
success
Engage with the research
community and make your
evidence needs clear
Funding support for formal
prioritisation processes
Targeted grant competitions to
drive research in priority areas
Require that research reports
summarise the evidence that
was already known on a topic
and show systematic review
evidence that supports the





Partner with researchers to do
evidence syntheses to inform
policy-making




Require evaluations to be
justified by systematic reviews
Support the publication of
systematic review protocols,
systematic reviews, evidence




Work with other stakeholders
to make rigorous evaluations
of all AMR programmes the
norm
Working with researchers, plan
the evaluation strategy for a
programme or policy before
launching the programme or
policy
Strategic funding support for
evaluations of policy
interventions and for policy-
research partnerships to facilitate
this research









needs of policy-makers (e.g.
including equity and cost-
effectiveness)
Decide in advance what
information and evidence you




when awarding grants to
support AMR policy research
Ensure timely peer review and
publication of research to





Use theory, frameworks and
logic models in the
intervention design phase to
frame how and why an
intervention is expected to
work
Use theory, frameworks and logic
models when planning policy
interventions to clarify how and
why an intervention is expected
to work
Do not fund interventions that
do not employ theory,
frameworks or logic models to
describe how and why the
intervention is expected to work
Require authors to report on
their use of theory, frameworks,
and logic in the design and
conduct of AMR interventions
Better design
of evaluations
Use the most rigorous
possible evaluation designs to
minimise bias and maximise
generalisability
Embrace research evaluation to
understand what, when, why and
how and intervention works
Studies using weak study
designs (e.g. uncontrolled before
and after designs) should not be
funded
Refrain from publishing studies
that use poor quality methods
such as uncontrolled before and










(based on rigorous evaluation) to
enhance the effectiveness of
extant policies
Provide funding support for
head-to-head trials






Develop a set of core
outcome measures for AMR
research
Partner with researchers to
ensure that core outcome
measures address your key
evidence needs
Funding support for the
development of an AMR core
outcome set
Require use of core outcome
measures in funded applications
Require researchers to use the





Commit to full and
transparent reporting of
studies
Use reporting guidelines and
checklists to fully report a
study
Register intervention
protocols to reduce the risk of
publication bias
Avoid ‘spin’ especially with
weak evaluative designs
Publish or make available reports
on the effectiveness of policy
interventions and efforts to
improve them
Make public the details of
funded interventions
Require full and transparent
reporting of studies
Require researchers to register
the protocols of their
interventions
Require authors to use the
relevant research reporting
guidelines and checklists







and embrace open data and
open access opportunities







Take advantage of opportunities
to borrow and adapt policy
interventions from other contexts
Make available data on policy
interventions in your setting to
promote uptake in other
contexts and ensure that
ineffective policy is not
duplicated in other settings
Provide funding for open access
publishing, open data-sharing
platforms, cross programme col-
laborations and living systematic
reviews
Increased commitment and
support for open access
publication
AMR antimicrobial resistance
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trials and systematic reviewing — both of which use
protocol registration to reduce publication bias and to
enable other researchers to see whether a research study
on a particular topic is ongoing — have benefited from
the support of research funders, journals and research
ethics boards to promote these efforts to improve re-
search reporting [67]. Along with trial registration, re-
searchers, governments and other implementing
organisations should commit to full and transparent
reporting of study results in open access journals, to
making datasets available to other researchers and en-
gaging in knowledge translation.
Researchers should also embrace the use of reporting
guidelines and checklists to overcome common report-
ing challenges such as not describing the intervention
specifically enough to allow replication [21, 50], using
the same description to represent different types of in-
terventions [68], using different terminology to repre-
sent the same content [69, 70], and repetition without
improvement [71]. The TIDieR tool [72] for describing
and replicating interventions, and its extension TIDieR-
PHP [73] for population health and policy studies, are
both useful tools for researchers to ensure that their
intervention has been thoroughly described. The
SQUIRE checklist [74] for quality improvement inter-
ventions, the CONSORT statement [75] for RCTs and
its many extensions to cluster RCTs [76], stepped
wedge trials [56], pilot studies [77], pragmatic trials
[78], and the Equator Network [79] are all useful tools
to ensure the full reporting of methods and findings
within a study report.
Shared learning opportunities
Researchers need to embrace open data and open access
opportunities to widely disseminate AMR research
findings.
The principle of shared learning is familiar to re-
searchers and embedded in much of health research. A
key question facing the field is how best to promote this
ideal when working with stakeholders to develop effect-
ive and efficient AMR policy interventions. However, as
many governments embrace nudge units, innovation
hubs and radical incrementalism [43], there is an oppor-
tunity for researchers to reiterate the substantial benefits
of shared learning. Many new methodological tools can
support these efforts – data sharing platforms (e.g. the
World Wide Antimalarial Resistance Network,
WWARN [80]) and open-access information repositories
will both go a long way to ensuring the evidence gener-
ated from policy experiments and intervention evalua-
tions can support shared learning. Likewise, living
systematic reviews, which are continually updated as
new evidence is generated [81], will also help ensure that
new policies are planned based on current evidence.
Conclusions
Although the threat posed by AMR has been well-
known for many decades, recent escalation in
multidrug-resistant and extensively drug-resistant bac-
terial infections has elevated AMR to a more prominent
position on the international political agenda. Substantial
work is ongoing at the national level to address domestic
AMR concerns [19], and there are robust conversations
at the international level about pursuing more large-
scale, coordinated efforts to mitigate the AMR threat
such as an international legal treaty on AMR [8, 11, 82–
84]. Innovative approaches have been taken to research
funding (e.g. JPIAMR [85]), health systems strengthening
(e.g. Accreditation Canada [86]), and global policy moni-
toring (e.g. WHO [19]).
These national and international efforts require sub-
stantially more evidence for the effectiveness and
feasibility of AMR policy interventions than is cur-
rently available. However, this gap provides an oppor-
tunity for researchers to engage in a meaningful
conversation about the importance of evidence-
informed policy-making for AMR. Mitigating the
threat posed by AMR will also require substantial col-
laboration among researchers and policy-makers.
Table 1 describes many of the ways in which research
funders, publishers and policy-makers can jointly sup-
port researchers and facilitate action across the prior-
ities identified in this framework. With their ability to
strategically fund innovative research, encourage re-
searchers to use rigorous study designs and reporting
checklists, and facilitate shared learning, these part-
ners have an opportunity to amplify researchers’ calls
for better AMR practice.
As we have highlighted, it is increasingly important to
strengthen the scientific evidence base on AMR policy
interventions, to learn from existing policies and pro-
grammes, and integrate scientific evidence into the glo-
bal AMR response [6]. This framework offers a path
forward, increasing local and global cooperation, and
overcoming common limitations in existing research on
AMR policy interventions.
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